Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) have received a consensus rating of “Buy” from the six brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $26.00.

KALV has been the topic of a number of recent research reports. Roth Capital initiated coverage on Kalvista Pharmaceuticals in a report on Tuesday, July 10th. They issued a “buy” rating and a $20.00 target price on the stock. ValuEngine upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd. Zacks Investment Research upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a report on Wednesday, September 12th. Finally, Cantor Fitzgerald initiated coverage on Kalvista Pharmaceuticals in a report on Friday. They issued a “buy” rating and a $32.00 target price on the stock.

In related news, Director Albert Cha bought 1,058,824 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $18,000,008.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 49.10% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of KALV. Eventide Asset Management LLC grew its holdings in shares of Kalvista Pharmaceuticals by 26.9% in the 1st quarter. Eventide Asset Management LLC now owns 900,000 shares of the specialty pharmaceutical company’s stock worth $8,532,000 after acquiring an additional 191,000 shares during the last quarter. Stanley Laman Group Ltd. grew its holdings in shares of Kalvista Pharmaceuticals by 48.3% during the second quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock valued at $545,000 after buying an additional 21,861 shares in the last quarter. Spark Investment Management LLC purchased a new position in shares of Kalvista Pharmaceuticals during the second quarter valued at $108,000. BlackRock Inc. grew its holdings in shares of Kalvista Pharmaceuticals by 203.8% during the second quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 10,871 shares in the last quarter. Finally, DRW Securities LLC grew its holdings in shares of Kalvista Pharmaceuticals by 37.3% during the second quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock valued at $167,000 after buying an additional 5,600 shares in the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

Shares of KALV stock traded up $1.99 during mid-day trading on Friday, hitting $19.99. 1,294 shares of the stock traded hands, compared to its average volume of 112,541. Kalvista Pharmaceuticals has a twelve month low of $6.65 and a twelve month high of $18.90. The stock has a market cap of $204.54 million, a PE ratio of -12.54 and a beta of 3.07.

Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.14). The company had revenue of $3.72 million during the quarter, compared to analyst estimates of $4.11 million. Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%. sell-side analysts predict that Kalvista Pharmaceuticals will post -1.69 EPS for the current year.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Story: Understanding Analyst Recommendations

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.